Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. Issue 6 (June 2014)

• Record Type: Journal Article
• Authors: Siddiqui, Ali A; Jones, Elizabeth; Andrade, Darren; Shah, Apeksha; Kowalski, Thomas E; Loren, David E; Chipitsyna, Galina; Arafat, Hwyda A
• Is Part Of: Journal of gastroenterology and hepatology. Volume 29:Issue 6(2014:Jun.)
• Page Start: 1321
• Page End: 1327
• Publication Date: 2014-06
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12561
• Languages: English
• ISSNs: 0815-9319

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jgh12561-sec-0001" sec-type="section"> <title>Background and Aim</title> <p>Osteopontin (OPN) is a phosphoprotein that activates pathways that induce cancer cell survival and metastasis. Our aim was to examine the expression pattern of OPN splice variants a, b, and c in fine‐needle aspirates and to determine their correlation with stage‐adjusted pancreatic ductal adenocarcinoma (PDA) survival.</p> </sec> <sec id="jgh12561-sec-0002" sec-type="section"> <title>Methods</title> <p>Endoscopic ultrasound‐guided fine‐needle aspiration (EUS‐FNA) was performed in patients with solid pancreatic masses. The tissue was collected and analyzed for the expression of OPN isoforms by reverse transcription–polymerase chain reaction. Survival curves of stages and overexpression of OPN splice variants (a, b, c) were estimated according to the Kaplan–Meier and the log‐rank test.</p> </sec> <sec id="jgh12561-sec-0003" sec-type="section"> <title>Results</title> <p>EUS‐FNA was performed in 46 patients with solid pancreatic lesions (40 PDA and 6 chronic pancreatitis). OPNa was highly expressed in 39/40 (98%), OPNb in 24/40 (60%), while OPNc was present in 10/40 (25%) of PDA samples. The median survival was lower in patients whose fine‐needle aspiration (FNA) samples expressed OPNb than those without (406 days <italic>vs</italic> 749 days, <italic>P</italic> = 0.049). There was no significant difference in survival in patients with OPNc. Cox proportional hazard model demonstrated that OPNb expression had a trend toward decrease overall survival (<italic>P</italic> = 0.06), with these patients having a hazard of death three times higher than those without. OPNc was found to significantly correlate with metastatic disease (<italic>P</italic> = 0.009) in PDA patients.</p> </sec> <sec id="jgh12561-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our data show for the first time that in FNA samples, there is a strong association between OPNc and presence of metastasis in PDA, and OPNb and poor survival.</p> </sec> </abstract>